Entera Bio (ENTX) Gross Margin (2019 - 2024)

Entera Bio's (ENTX) quarterly Gross Margin came in at 15.79% in Q2 2024, down 63.16% on a QoQ basis from 42.86% in Q4 2022.

Entera Bio (ENTX) Gross Margin (2019 - 2024) Analysis & Trends

Entera Bio (ENTX) has 5 years of Gross Margin data on file, last reported at 15.79% in Q2 2024.

Quarterly Gross Margin changed N/A year-over-year to 15.79% in Q2 2024, while the trailing twelve-month figure through Mar 2025 was 4.04% (changed N/A YoY) and the FY2024 annual result came in at 4.97%, changed N/A from the prior year.
Gross Margin declined to 15.79% in Q2 2024, from 42.86% in the prior quarter.
In the past five years, Gross Margin ranged from a high of 53.57% in Q3 2021 to a low of 9.17% in Q2 2021.
A 4-year average of 30.34% and a median of 25.0% in 2022 frame the typical range for Gross Margin.
The widest YoY moves for Gross Margin: up 2528 bps in 2022, down 3291 bps in 2022.
Tracing ENTX's Gross Margin over 4 years: stood at 40.38% in 2020, then plunged by 56 bps to 17.58% in 2021, then surged by 144 bps to 42.86% in 2022, then sank by 63 bps to 15.79% in 2024.
The last three Gross Margin figures came in at 15.79% (Q2 2024), 42.86% (Q4 2022), and 25.0% (Q3 2022), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.47 Bn	131.61 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	86.36 Bn	78.37 Bn	3.93 Bn	91.59%
3	Argenx Se	65.16 Bn	59.98 Bn	1.37 Bn	90.43%
4	Moderna	58.99 Bn	53.85 Bn	52.00 Mn	35.86%
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.74 Bn	28.43 Bn	992.69 Mn	76.90%
7	BioNTech SE	28.01 Bn	9.61 Bn	668.28 Mn	63.27%
8	Insmed	27.50 Bn	26.34 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.28 Bn	26.45 Bn	-	-
10	Entera Bio	165.98 Mn	154.68 Mn	-	-

Download Data